InterVenn Biosciences Announces Positive Interim Clinical Trial Results and Appoints Biotech Veteran Klaus Lindpaintner, M.D. as Chief Scientific and Medical Officer
InterVenn Biosciences, a company in the life sciences and technology sector, is pleased to announce that the interim results of its prospective clinical trial for its Ovarian Cancer Clinical Decision Tool have successfully exceeded its milestones and expectations.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20191118005886/en/
Klaus Lindpaintner, M.D. joins Intervenn Bio as Chief Scientific and Medical Officer (Photo: Busi...